Unlocking nicotinic selectivity via direct C‒H functionalization of (−)-cytisine by Rego Campello, Hugo et al.
ArticleUnlocking Nicotinic Selectivity via Direct C‒H
Functionalization of ()-CytisineHugo Rego Campello, Silvia G.
Del Villar, Aure´lien Honraedt, ...,
Adrian J. Mulholland, Susan
Wonnacott, Timothy Gallagher
t.gallagher@bristol.ac.uk
HIGHLIGHTS
Efficient and highly flexible C(10)
functionalization of ()-cytisine
Ligands with enhanced selectivity
for a4b2 nicotinic acetylcholine
receptor subtypes
Reduced affinity and loss of
agonist profile at a7
Receptor features that link to
subtype selectivity are identifiedEfficient access to C(10) of ()-cytisine via C‒H activation provides access to
enantiomerically pure nicotinic acetylcholine receptor ligands that target the high-
affinity nicotine a4b2 subtype with enhanced selectivity. These C(10) cytisine
variants retain a partial agonist profile at the a4b2 subtype but, critically, display
negligible activity at the a7 receptor subtype. Using computational methods,
Gallagher and colleagues link receptor selectivity to key protein residues
associated with, as well as beyond, the immediate ligand binding site.Rego Campello et al., Chem 4, 1710–1725
July 12, 2018 ª 2018 The Author(s). Published
by Elsevier Inc.
https://doi.org/10.1016/j.chempr.2018.05.007
ArticleUnlocking Nicotinic Selectivity via
Direct C‒H Functionalization of ()-Cytisine
Hugo Rego Campello,1 Silvia G. Del Villar,2 Aure´lien Honraedt,1 Teresa Minguez,2
A. Sofia F. Oliveira,1,3 Kara E. Ranaghan,1 Deborah K. Shoemark,3 Isabel Bermudez,2 Cecilia Gotti,4
Richard B. Sessions,3 Adrian J. Mulholland,1 Susan Wonnacott,5 and Timothy Gallagher1,6,*The Bigger Picture
Molecular locksmithing is the use
of precision chemical keys for
biological locks. Nicotinic
acetylcholine receptors (nAChR)
associated with acetylcholine
neurotransmission are linked to
public health issues, notably
tobacco addiction. Why is this
important? Smoking kills seven
million people annually and
imposes a huge burden in terms of
healthcare and lost productivity.
The ability to design a molecule to
achieve high receptor selectivity isSUMMARY
Differentiating nicotinic acetylcholine receptors (nAChR) to target the high-
affinity nicotine a4b2 subtype is a major challenge in developing effective addic-
tion therapies. Although cytisine 1 and varenicline 2 (current smoking-cessation
agents) are partial agonists of a4b2, these drugs display full agonism at the a7
nAChR subtype. Site-specific modification of ()-cytisine via Ir-catalyzed C‒H
activation provides access to C(10) variants 6–10, 13, 14, 17, 20, and 22, and
docking studies reveal that C(10) substitution targets the complementary
region of the receptor binding site, mediating subtype differentiation. C(10)-
modified cytisine ligands retain affinity for a4b2 nAChR and are partial agonists,
show enhanced selectivity for a4b2 versus both a3b4 and a7 subtypes, and
critically, display negligible activity at a7. Molecular dynamics simulations link
the C(10) moiety to receptor subtype differentiation; key residues beyond the
immediate binding site are identified, and molecular-level conformational
behavior responsible for these crucial differences is characterized.paramount for the success of
smoking cessation: poor
selectivity is typically
accompanied by (adverse) side
effects. We have modified
cytisine, a known ‘‘nicotinic
activator,’’ in a very direct and
versatile manner to suppress a
particular characteristic:
activation of the a7 subtype of
nAChR. Computational molecular
simulation of the protein-ligand
complexes links these structural
changes to a ligand’s activity,
facilitating the design of precision
‘‘molecular keys’’ for better
discrimination of receptor
subtypes and offering the
potential of more targeted
therapies.INTRODUCTION
Validated links exist between neuronal nicotinic acetylcholine receptors (nAChR)1–4
and a range of neurodegenerative5 and psychiatric diseases.6 Interest in these
conditions, together with the broader public health issue of tobacco consumption
and addiction,7,8 a global challenge highlighted by the landmark World Health
Organization Framework Convention on Tobacco Control,9 has driven the discovery
and evaluation of small molecule ligands for therapeutic intervention, notably for
smoking cessation.10,11 These molecules are often derived from natural product
leads, such as nicotine, but a continuing goal is to identify ligands with higher
selectivity for targeting nAChR subtypes such as a4b2 (the prime receptor for
smoked nicotine because of its high-affinity nicotine binding sites) coupled with
sufficient bioavailability to enable central nervous system penetration.12,13
Our activity in this area is focused on ()-cytisine 1 (Figure 1).14 Currently marketed
for smoking cessation as Tabex, ()-cytisine, which is isolated from Cytisus laburnum
(Golden Rain acacia), has been used in eastern Europe for well over 50 years.15,16
The partial agonist profile of 1 at a4b2 nAChR differentiates this natural product
from full agonists, such as acetylcholine. Two recent controlled clinical trials have re-
ported17,18 further support for the effectiveness of cytisine 1 for smoking cessation.
Cytisine, which is more effective than nicotine replacement therapy, offers the
potential of a readily available and efficacious, as well as cost-effective, smoking-
cessation protocol.19 A synthetic variant, varenicline 2 (launched in 2006 as Champix
and Chantix; Figure 1)20–23 offers a broadly comparable profile with that of 1 for a4b21710 Chem 4, 1710–1725, July 12, 2018 ª 2018 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Cytisine 1 and Varenicline 2, Nicotinic Partial Agonists at a4b2 nAChR, and Full
Agonists at a7 nAChR
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https://doi.org/10.1016/j.chempr.2018.05.007nAChR, and these commercial products have led to partial agonism being regarded
as a key feature for successful intervention to combat nicotine addiction.10 However,
both cytisine24 and varenicline25 are also full agonists (in vitro) at the a7 (where
varenicline 2 is more potent than cytisine 126) and a3b4 nAChR subtypes, albeit
with differing potencies, but nevertheless contributing to the potential of off-target
side effects. A contemporary goal, therefore, is to develop partial agonists for the
a4b2 nAChR with enhanced nAChR subtype selectivity.
The biological target, the two agonist binding sites of a4b2 nAChR, is located at the
interface of a and b subunits of this pentameric receptor.1,2 The a subunit contributes
the primary component comprising key aromatic amino acids and the highly conserved
C loop. This accommodates (protonated) N(3) of 1 via an interplay of cation-p and
hydrogen-bonding interactions27–29 and is an interaction that is highly sensitive to struc-
turalmodification in this regionof the ligand.30Thepyridonemoietyof1, however, binds
within the complementary region of the site provided by the adjacent b subunit (or the
opposite face of an a7 subunit in the homomeric a7 nAChR). This region influences sub-
type selectivity for agonists, and in the case of cytisine, higher selectivity for the a4b2
nAChRsubtypeovera3b4 is associatedwith substitutionatC(10).31–33For example, rela-
tive to cytisine 1 (which is 150-fold more selective at a4b2 than a3b4), the C(10) methyl
analog (racemic variant of 10 below) shows a 3,500-fold selectivity in binding affinity
for the a4b2 (relative to a3b4) nAChR subtype.32 This provides an impetus to explore
modification of the pyridone moiety of 1 as an attractive avenue for further enhancing
nAChR subtype selectivity. However, previous access to C(10) substituted cytisine li-
gands has required lengthy synthetic sequences (at least ten chemical steps) limiting
both the number and variety of C(10) options available. Moreover, only racemic ligands
have been reported to date;31–33 although the (+)-enantiomer ((+)-1) lacks a nicotinic
profile,34 the broader characteristics (e.g., toxicology) of (+)-1 remain unclear, high-
lighting the value of targeting enantiomerically pure variants. Accordingly, there is a sig-
nificant hurdle to overcome: given the inherent bias of the pyridone moiety for electro-
philic substitution at C(9) and C(11), how do we specifically target C(10) of ()-cytisine 1
directly, efficiently, and with the ability to access a wide range of structural variation?
RESULTS
Synthesis of ()-Cytisine C(10) Variants
Here we demonstrate how to manipulate directly ()-cytisine 1 at C(10) in a highly
versatile manner. This chemistry leads efficiently and flexibly to cytisine variants
with (1) enhanced a4b2 selectivity (versus both a3b4 and a7) that retain the essential
partial agonist profile suited to smoking cessation, and (2) that also show a negligible
agonist profile for a7 nAChR. Functionalization of ()-1 has been achieved by
highly efficient Ir-catalyzed borylation within the pyridone moiety35 of cytisine.
This C‒H activation process occurs exclusively at C(10) within the pyridone ringChem 4, 1710–1725, July 12, 2018 1711
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Scheme 1. Ir-Catalyzed C(10) Borylation of N-Boc cytisine 3
Reagents and reactions conditions were as follows: (a) Boc2O, Na2CO3, THF, H2O (93%);
(b) [Ir(COD)(OMe)]2 (1 mol %), dtbpy (2 mol %), B2pin2 (0.70 equiv), THF (0.7 M with respect to 3),
reflux (100% conversion by 1H NMR); (c) CuBr2 (3 equiv), MeOH, H2O, air (83%). Abbreviations: Boc,
CO2t-Bu; B2pin2, bis(pinacolato)diboron; dtbpy, 4,4
0-di-tert-butyl-2,20-dipyridyl; Me4phen, 3,4,7,8-
tetramethyl-1,10-phenanthroline; THF, tetrahydrofuran.(Scheme 1) and the functionality introduced (i.e., the C(10) boronate ester 4 or
derived bromide 5) provides essentially unfettered means of varying the C(10)
substituent. A significant consequence of this chemistry is that all resulting C(10)
ligands produced are single enantiomers.
Ir-catalyzed C‒H activation and C(10) site-specific borylation can be conducted with
()-cytisine 1 itself but in our hands this required an excess (1.5–3.0 equiv) of B2pin2
and the instability of the resulting 10-(Bpin)cytisine proved to be a limitation. N-Boc
cytisine 3 (available in high yield from ()-cytisine 1) provides, however, an optimal
substrate, offering excellent chemical efficiency and conversion (only 0.70 equiv of
B2pin2 needed), very good product stability, and easy scale-up: borylation of 3 to
give 4 has been done on a 5-g scale (with 0.6 mol % of [Ir(COD)(OMe)]2). No purifi-
cation was required and crude 4was used directly as illustrated by conversion to bro-
mide 5 (in 77% overall yield over three steps) from ()-1 (Scheme 1). Further and
importantly, this chemistry offers significant flexibility in terms of the scope of down-
stream processing options and the range of C(10) cytisine variants that are available.
Intermediates 4 and 5 offer highly complementary synthetic options for exploring a
comprehensive structure-activity profile for the a4b2 nAChR by using enantiomeri-
cally pure cytisine-based ligands that are easily isolated and purified. Here, we
present a representative selection of these C(10) ligands together with preliminary
biological data: binding affinity and functional potency (agonist potency and effi-
cacy) profiles that demonstrate nAChR subtype selectivity. These data, combined
with molecular modeling and simulation, allow us to propose a rationale for the
subtype selectivity profiles we have observed.
Exploiting the reactivity profiles of both 4 and 5 is illustrated in Scheme 2. Use of the
crude 10-borylated adduct 4 via direct oxidation or copper-catalyzed Chan-Lam
coupling led to the 10-hydroxy and 10-methoxycytisine derivatives 6 and 7, respec-
tively, after N-Boc cleavage (4) or inverse sense (via 5), provided the 10-arylated
adducts 8 and 9. Chemistry using 4 has also been exploited to introduce other
heteroatom-based substituents at C(10) as well as a wide range of other 10-aryl
and heteroaryl variants, and full details of this will be reported in due course.
The 10-bromo derivative 5 also enables a variety of C‒C bond-forming processes to be
exploited.AlthoughStille-typecouplingusingMe4Snprovided the10-methylderivative
10 in essentially quantitative yield, toxic alkyltinsareavoidable, and10wasalsoavailable
in (an unoptimized) 64% yield from boronate ester 4 via Pd-catalyzed methylation1712 Chem 4, 1710–1725, July 12, 2018
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Scheme 2. Transformations Based on 4 and 5 to Provide C(10)-Substituted Cytisine Ligands
Yields shown below are for transformations other than (b), i.e., N-Boc cleavage. This step was
common to all examples except for 7, 8, and 14 (where trifluoroacetic acid [TFA] and
dichloromethane [DCM] were used), and overall isolated yields (i.e., including b, where
appropriate) are shown under the product structure. Final products were isolated as HCl salts
except for 7, 8, and 14, which were isolated as free bases. Reagents and reactions conditions were
as follows: (a) 30% aqueous H2O2, NaOH, room temperature (RT) (79%); (b) HCl in MeOH, RT; (c) (1)
CuSO4, MeOH, KOH, MS 4A˚, O2 (balloon), 65
C; (2) TFA, DCM, RT (69% overall); (d) (1) 4-BrC6H4Me,
Pd(PPh3)4, K2CO3, DME/H2O, 80
C; (2) TFA, DCM, RT (41% overall); (e) BrC6F5, PdCl2(PPh3)2,
Cs2CO3, THF, reflux (99%); (f) Me4Sn, PdCl2(PPh3)2, PhMe, 100
C (99%); ligand 10 is also available
from 4 via Pd-catalyzed methylation (see main text and Supplemental Information); (g) Pd(OAc)2,
dppp, Et3N, DMF, MeOH, CO, 80
C (86%); (h) LiAlH4, THF, 78C (62%); (i) (1) 4MeC6H4B(OH)2,
Pd(PPh3)4, K2CO3, DME/H2O, 80
C; (2) TFA, DCM, RT (53% overall); (j) TFA, DCM, RT (93%).
Abbreviations: DCM, dichloromethane; DME, dimethoxyethane; dppp, bis(diphenylphosphino)
propane; TFA, trifluoroacetic acid.involving MeI. Pd-catalyzed carbonylation of 5 gave ester 11, reduction of which gave
12, and subsequent Boc deprotection generated 10-(hydroxymethyl)cytisine 13; both
10 and 13 have previously been prepared by Kozikowski and co-workers31,32 but onlyChem 4, 1710–1725, July 12, 2018 1713
NNBoc
O
Br
N
NR
O
Y
N
NR
O
Y
21 Y=CMe3; R=Boc
22 Y=CMe3; R=H·HCl (43% from 5)
15 Y=CH=CH2; R=Boc
16 Y=CH2Me; R=Boc
(a)
(c)
17 Y=CH2Me; R=H·HCl (79% from 5)
(b)
(c)
5
N
NR
O
Y
18 Y=C(Me)=CH2; R=Boc
19 Y=CHMe2; R=Boc
20 Y=CHMe2; R=H·HCl (87% from 5)
(e)
(c)
(f)
(d)
Scheme 3. C(10)-Alkyl Variation of Cytisine
Yields shown below are for transformations other than (c), i.e., N-Boc cleavage. This step was
common to all examples, and overall isolated yields (i.e., including c) are shown under the product
structure. Final products were isolated as HCl salts. Reagents and reactions conditions were as
follows: (a) (CH2=CHBO)3$py, K2CO3, PdCl2(PPh3)2, dioxane, water, 90
C (86%); (b) Pd/C, H2, MeOH
(95%); (c) HCl in MeOH, RT; (d) CH2=C(Me)Bpin, NaHCO3, Pd(PPh3)4, water, dioxane, 60
C (94%);
(e) TolSO2NHNH2, K2CO3, MeCN, reflux (95%); (f) Me3CMgCl, CuI, THF, 40C (42%).as racemates andwith lengthy sequences (at least ten steps). Bromide 5 is also effective
in Suzuki-Miyaura cross-coupling in that it offers an alternative entry to 8. Finally, 10-halo
variants were of interest, and for that reason, 10-bromocytisine 14 was prepared. The
developmentofmore focusedstructural libraries, guidedby thebiological profiles asso-
ciatedwithC(10) substituted cytisine leads, is alsonow fully enabledby readyavailability
on scale of both 4 and 5. This, in turn, underscores the value of being able to achieve the
direct, 100% regioselective, and highly efficient C‒H functionalization of N-Boc cytisine
3 (shown in Scheme 1).
Probing Subtype Selectivity as a Function of C(10) Alkyl Variation
The level of subtype differentiation (compared with cytisine 1) observed for
10-methylcytisine 10 (see below) prompted us, by way of exemplification, to
explore one focused library by varying the C(10) alkyl residue. This largely limits
changes to bulk and lipophilicity, and with the flexibility associated with the reac-
tivity of bromide 5, the C(10) ethyl, iso-propyl, and tert-butyl variants 17, 20, and
22 were synthesized (Scheme 3). A Suzuki-Miyaura cross-coupling approach
enabled access to the 10-ethenyl adduct 15, and alkene reduction of this followed
by Boc cleavage of 16 gave the 10-ethyl cytisine variant 17. An analogous cross-
coupling provided the isopropenyl adduct 18, which was reduced to give 19
and deprotected to provide 20. Direct introduction of a tert-butyl moiety is achiev-
able with a copper catalyst under the Kumada-Corriu-Tamao reaction developed
by Hintermann et al.36 This chemistry, which was developed with haloazines and
diazines, had not been applied previously to 2-pyridones but is effective in
providing adduct 21. Deprotection then afforded 22, completing a homologous
series of ligands from cytisine 1 (H at C(10)) to 22 (tert-Bu at C(10)).
In Vitro Biological Evaluation
Binding Affinities
Two sets of biological data establish the superior selectivity of the ligands shown in
Schemes 2 and 3 for human a4b2 nAChR, supporting their potential as candidates
for smoking cessation. Binding-affinity profiles across three human nAChR subtypes1714 Chem 4, 1710–1725, July 12, 2018
Table 1. Affinity (Ki in nM) of C(10) Ligands for a4b2, a3b4, and a7 nAChR Subtypes
Ligand a4b2a a3b4a a7a a3b4/a4b2 a7/a4b2
Ki Ki Ki
()-Cytisine 1 1.27G 0.1 103G 16.4 691G 16.4 81.1 544
1.5b 220b – 147b –
6 14.7G 3.4 8,951G 2,434 15,000G 2,526 609 1,017
7 41G 6.7 8,452G 2,220 21,300G 7,976 206 520
8 14.1G 4.1 2,280G 760 5,630G 1,747 162 399
9 19.1G 5.7 154G 33 10,980G 4,485 8.1 575
10 2.60G 0.5 2,273G 868 5,027G 1,978 864 1,911
1.9b 6,700b – 3,526b –
13 36.8G 9.4 2,685G 910 116,000G 48,750 73 3,152
11b 10,000b – 909b –
14 1.77G 0.4 537G 131 323G 127 303 182
17 3.01G 0.4 5,723G 1,660 6,928G 2,326 1901 2301
20 12.5G 3.0 20,390G 5,150 96,500G 34,050 1,622 7,677
22 26.4G 4.8 70,620G 15,050 134,600G 60,275 2,675 5,098
aHeterologously expressed human receptors were used. a4b2 and a3b4 nAChR subtypes were expressed in HEK293 cells; human a7 nAChR was expressed in
SH-SY5Y human neuroblastoma cells. Binding was assessed with [3H]epibatidine for a4b2 and a3b4 nAChR subtypes and [125I]a-bungarotoxin for a7 subtype. Ki
values (in nM) were derived from the average value of three independent competition binding experiments for each compound on each subtype.
bBinding data (Ki nM) based on a4b2 and a3b4 rat subtypes reported
32 for ()-cytisine 1 and racemic ligands (G)-10 and (G)-13; corresponding data for a7 nAChR
subtype were not reported.(a4b2, a3b4, and a7) for a series of C(10) ligands, all as single enantiomers, are pre-
sented in Table 1 together with values for ()-cytisine 1 for comparison. Kozikowski
and Kellar32 have previously reported binding affinities for racemic 10-methyl and
10-(hydroxymethyl)cytisines ((G)-10 and (G)-13, respectively), and their data using
rat nAChR subtypes are included for comparison in Table 1. The modest differences
in Ki values between the present study and that reported earlier can be accounted
for by species (rat versus human) differences and/or their use of racemic ligands.
The data documented in Table 1 confirm that C(10)-substituted cytisine ligands have
preferential binding affinity for a4b2 nAChR versus a3b4 or a7 nAChR. All C(10)
ligands bind to a3b4 and a7 nAChR with a lower affinity than cytisine 1, except
10-(perfluorophenyl)cytisine 9, which has a similar affinity at a3b4 as 1, and bromide
14, which has a (modestly) higher affinity for a7 than does cytisine 1. Moreover, bind-
ing affinities in the high nanomolar range are retained for the a4b2 nAChR subtype,
such that bromide 14 and the 10-methyl and 10-ethyl derivatives 10 and 17 have
affinities comparable with that of cytisine 1.
Increasing the size of the C(10) alkyl substituent (using the ligand series outlined in
Scheme3) shows thatalthoughasmall lossofpotencyat thea4b2nAChRsubtype isasso-
ciatedwith the 10-isopropyl and 10-tert-butyl analogs 20and 22, these two ligands show
markedly increased levels of selectivity (5,000- to 7,000-fold) against the a7 subtype.
Functional Assays
In the second set of biological experiments, we evaluated the series of C(10)-
substituted ligands (6–10, 13, 14, 17, 20, and 22) over the concentration range
1 nM to 100 mM for their functional potency and efficacy as agonists by determining
their ability to activate currents in Xenopus oocytes heterologously expressing hu-
man a4b2, a3b4, or a7 nAChR subtypes (Figures 2A and 2B; Table S1). AcetylcholineChem 4, 1710–1725, July 12, 2018 1715
Figure 2. Functional Effects of C(10)-Substituted Cytisine Ligands on (a4)2(b2)3, (a4)3(b2)2, a3b4,
and a7 nAChR Subtypes
For a Figure360 author presentation of Figure 2, see http//dx.doi:10.1016/j.chempr.2018.05.
007#mmc4.
(A) Representative traces of the current responses of (a4)2(b2)3, (a4)3(b2)2, a3b4, and a7 nAChR
subtypes elicited by C(10)-substituted cytisine (Cy) ligands with the highest binding affinities for
a4b2 nAChRs (6, 8, 9, 10, and 17) tested at 100 mM. Current responses were measured by two-
electrode voltage-clamp recordings from Xenopus oocytes heterologously expressing (a4)2(b2)3
and (a4)3(b2)2 (the high and low acetylcholine [ACh] affinity stoichiometries, respectively), a3b4, or
a7 nAChR subtypes, as detailed in the Supplemental Information. Current responses to 100 mM
C(10) compounds were maximal responses for (a4)2(b2)3, (a4)3(b2)2, and a3b4 nAChR. Maximal
current responses were elicited by 1 mM ACh, 100 mM nicotine (Nic), 100 mM Cy 1, and 100 mM
varenicline 2 (Var) for comparison. a7 nAChR responses to C(10) ligands were submaximal when
tested at 100 mM and less than 1% of the maximal ACh response (Table S1). Maximal current
responses were elicited by 1 mM ACh, Nic, Cy 1, and Var 2. Arrowheads indicate compound
application onto Xenopus oocytes expressing (a4)2(b2)3 (black), (a4)3(b2)2 (blue), a3b4 (gray), and
a7 (red) nAChR.
(B) Relative efficacies of C(10)-substituted Cy ligands for activating (a4)2(b2)3, (a4)3(b2)2, a3b4, and
a7 nAChR subtypes; comparison with ACh, Nic, Cy 1, and Var 2. Relative efficacy was determined
with the following equation: (maximal response to test compound)/(maximal response to ACh)
(1 mM). The C(10)-substituted ligands shown were tested over a concentration range of 1 nM to
100 mM, and maximal responses were achieved at 100 mM C(10)-substituted ligand for (a4)2(b2)3,
(a4)3(b2)2, and a3b4 nAChR. At 100 mM, the compounds elicited submaximal current responses
when applied to a7 nAChRs. Values are the mean G SEM of six or seven independent experiments
carried out on oocytes from five or six different Xenopus donors. Functional potencies (EC50) were
estimated for ligands with agonist efficacy greater than 0.1 by non-linear regression with GraphPad
software and are shown in Table S1.
1716 Chem 4, 1710–1725, July 12, 2018
was assayed in parallel as a fully efficacious, non-selective agonist. Nicotine, cytisine
1, and varenicline 2 were also included for comparative purposes. We examined the
two stoichiometries of the a4b2 nAChR by separately expressing the human recep-
tors (a4)2(b2)3 (high sensitivity for acetylcholine and nicotine) and (a4)3(b2)2 (low
sensitivity for acetylcholine and nicotine).37
The C(10) ligands behaved as partial agonists at (a4)2(b2)3 and (a4)3(b2)2 receptors
and produced responses that were much smaller than those of acetylcholine but
of similar magnitude to those currents produced by cytisine 1 (Figure 2A). Maximal
responses were achieved by concentrations of 30–100 mM, indicating potency com-
parable with that of the parent cytisine 1. Our ligands also activated a3b4 nAChRs
but with markedly lower efficacy than observed for cytisine 1. Consistent with their
low binding affinities at a7 nAChR (Table 1), C(10) cytisine ligands applied over
the same concentration range (1 nM–100 mM) showed negligible activity at a7
nAChR; at the highest concentration (100 mM), they either failed to induce any
measurable current responses (6) or activated currents that were less than 1% of
the maximal acetylcholine response (ligands 7–10, 13, 14, and 17 in Figure 2B; func-
tional data relating to the alkyl series, including ligands 20 and 22, are shown in
Figure S3).
When tested at higher concentrations (up to 3 mM), with the exception of ligand 6,
which displayed no agonist activity at a7 nAChR, the C(10) ligands activated current
responses with increased amplitudes (Table S1). For ligands 7, 9, 13, 20, and 22, the
amplitudes of the responses were too low for constructing meaningful concentra-
tion-response curves. However, for compounds 8, 10, 14, and 17, it was possible
to generate full concentration-response curves: the estimated efficacies for these
ligands were 20%–40% of that of acetylcholine. Their potencies at a7 nAChR were
in the mM range: 8, 1.55 G 0.35 mM; 10, 1.60 G 0.20 mM; 14, 1.58 G 0.15 mM;
17, 1.70 G 0.18 mM (Figure S2; Table S1). This is in marked contrast to the more
than two orders of magnitude greater potency and full agonism of cytisine 1 and
varenicline 2 at human (Figure 2), chick,24 and rat25 a7 nAChR.
Although the data shown in Figure 2 clearly demonstrate the partial agonist profiles
of the C(10)-substituted cytisine variants at a4b2 nAChR, the limited agonist efficacy
observed confounds accurate determination of their potency when the maximal cur-
rent is less than 10% of that achieved by a full agonist like acetylcholine. As a result,
we undertook further characterization of these C(10)-ligands at a4b2 nAChR to
explore their partial agonism and obtain quantitative determinations of functional
potency. We achieved this by assessing the ability of these ligands to act as
competitive antagonists. This strategy is based on the rationale that a partial
agonist fully occupies the agonist binding site while having low efficacy in activating
the receptor: in occupying the binding site, a ligand will prevent other agonists from
binding and activating the receptor; thus, in this circumstance, the partial agonist
also acts as a partial competitive antagonist.38 Indeed, this is the premise for the
efficacy of varenicline as a smoking-cessation agent.10 Where agonist efficacy is
very low, as for the C(10)-substituted cytisines described here at nAChR subtypes,
evaluation of the propensity of these ligands to act as competitive antagonists
over a range of concentrations offers a more robust means of assessing their
functional potency.39 This is illustrated in Figure S1 for inhibition by cytisine 1 of
acetylcholine-evoked responses of (a4)2(b2)3 and (a4)3(b2)2 nAChR. Note that the
inhibition curve falls short of 100% inhibition, consistent with the partial agonist
action of cytisine (magnified in the central panels of Figure S1). The inhibition curve
allows determination of the concentration of cytisine 1, producing 50% inhibitionChem 4, 1710–1725, July 12, 2018 1717
Figure 3. Competitive Antagonist Activity of C(10)-Substituted Cytisine Derivatives 10 and 17 on
(a4)2(b2)3, (a4)3(b2)2, and a7 nAChR Subtypes
The ability of ligands 10 and 17 to inhibit current responses elicited by ACh in Xenopus oocytes
expressing (a4)2(b2)3 (A), (a4)3(b2)2 (B), and a7 (C) nAChR subtypes was determined by
two-electrode voltage-clamp recording as described in the Supplemental Information. Oocytes
were stimulated with ACh at a concentration that produced 80% of its maximum response
(EC80 concentration): 30 mM for (a4)2(b2)3 (A) and 300 mM for (a4)3(b2)2 (B) and a7 (C) nAChR in the
presence or absence of 10 or 17, which were tested over a broad range of concentrations. Current
responses in the presence of test ligand were compared with the control response to ACh alone
(taken as 1.0) for construction of dose-response curves. Data points are the mean G SEM from six
independent determinations.(half maximal inhibitory concentration [IC50] 0.61 mM and 7.30 mM for (a4)2(b2)3 and
(a4)3(b2)2 nAChR, respectively, Table S2). The latter value accords well with the
directly estimated EC50 of 5.3 mM for activation of (a4)3(b2)2 nAChR by cytisine 1
(Table S1), which validates this approach for assessing potency. The lower agonist
efficacy of the (a4)2(b2)3 nAChR subtypes precluded derivation of EC50
directly. Similarly, C(10)-substituted cytisine ligands inhibited acetylcholine-evoked
responses of (a4)2(b2)3 and (a4)3(b2)2 nAChR expressed in Xenopus oocytes with
residual activation that correlates with the directly determined agonist efficacy (Fig-
ures 3A and 3B; Table S2). In all cases, ligands were more potent inhibitors of the1718 Chem 4, 1710–1725, July 12, 2018
(a4)2(b2)3 stoichiometry. Consistent with the binding data (Table 1), the most potent
inhibitors of a4b2 nAChR were the 10-methyl and 10-ethyl cytisine derivatives 10
and 17, which gave IC50 values (0.88 and 0.95 mM, respectively) comparable with
that of cytisine 1 (IC50 0.61 mM; Table S2).
We used the same approach to examine the ability of C(10)-substituted cytisine ligands
10 and 17 to inhibit acetylcholine-evoked responses from a7 nAChR (Figure 3C). This
experiment clearly demonstrated that neither of these ligands has any antagonist activ-
ity at concentrations below 1 mM. This confirms that these ligands lack the ability to
interact productively with a7 nAChR at sub-millimolar concentrations. This is consistent
with the low-affinity binding constants shown in Table 1 and is in marked contrast to cy-
tisine 1. Given the series of alkyl derivatives associated with Scheme 3, this correlation
between affinity (Table 1) and a7 function appears to extend to more sterically
demanding substituents, such as those present in 20 and 22 (Figure S3). However, it
would be premature to attribute (or indeed limit) this selectivity effect to substituent
volume.
In summary, the C(10)-substituted cytisine ligands described in this paper retain the
potent partial agonism of cytisine 1 at a4b2 nAChR, regarded as a fundamental prop-
erty for successful smoking-cessation agents.10 These ligands display a preference for
the (a4)2(b2)3 receptor stoichiometry, and that discrimination can be attenuated by vari-
ation, for example, of the size of a C(10) alkyl substituent. In contrast to cytisine 1, they
lack the ability to activate (or inhibit) a7 nAChR at therapeuticallymeaningful concentra-
tions, eliminating an interaction considered to be off-target for smoking cessation.22,23
Furthermore, although these C(10) ligands are also weak partial agonists at a3b4
nAChRs, observed efficacies at this subtype are consistently lower than those of cytisine
1 and varenicline 2 at a3b4 nAChR.25Moreover, the binding affinities of a3b4 nAChR for
the C(10) compounds (with the exception of 9) are markedly lower than that for cytisine
1. As a consequence, these C(10)-substituted cytisine variants (exemplified by the
C(10)-alkyl series 10, 17, 20, and 22) combine potent partial agonism with exceptional
selectivity for a4b2 nAChR, making them excellent lead candidates for further structural
and pharmacological development.
Computational Docking Studies and Molecular Dynamics Simulations
Recognition of the opportunities associated with achieving a specific modification of
cytisine at C(10) was guided by computational modeling of themode of binding (and
differences associated with that mode of binding) of a series of prototype ligands,
namely cytisine 1 and the C(10) hydroxyl and C(10) methyl cytisine analogs 6 and
10, respectively. We carried out this study by using appropriate crystallographic
data40,41 to derive human homology models in order to dock ligands into the
binding sites of the three key nAChR subtypes: a4b2, a3b4, and a7. These models
suggest three factors in the immediate environment of the agonist binding site to
rationalize the enhanced a4b2 receptor selectivity compared with that of a3b4
and a7 nAChR for 1, 6, and 10 in terms of binding affinities. Although this study
ultimately guided the selection of C(10) as the preferred site for modification,
it also provides a framework for interpreting the selectivity for C(10)-substituted
cytisine ligands presented in Table 1.
Ligands were docked into these three receptor subtypes in poses corresponding
to those observed in the crystal structures of the acetylcholine binding protein
(Ac-AChBP) (from Aplysia californica) with cytisine 1 and with varenicline 2
(PDB: 4BQT and PDB: 4AFT, respectively),40 and the resulting complexes were
relaxed by energy minimization. The Supplemental Information provides fullChem 4, 1710–1725, July 12, 2018 1719
Figure 4. Binding-Site Orientations of Nicotine and Cytisine 1 in a4b2, a3b4, and a7 nAChR Subtypes
For clarity, all residue numbering refers to the analogous positions in the PDB: 5KXI crystal structure of the (a4)2(b2)3 nAChRwith nicotine bound.
41W57 is analogous
to the TrpD referred to by Tavares et al.,29 and W156 is analogous to TrpB. The solid sphere corresponds to the C(10) position within cytisine 1.
(A) The position of nicotine in the crystal structure of a4b2 PDB: 5KXI41 (a subunit in cyan, b subunit in magenta, and nicotine in green).
(B) Cytisine 1 docked into the binding pocket of a4b2 (a subunit in cyan, b subunit in magenta, and cytisine 1 in purple); Video S1.
(C) Cytisine 1 docked into the model of human a3b4 (a subunit in blue, b subunit in mauve, and cytisine 1 in purple). Note the residues immediately lining
the binding pocket: F119 (a4b2) is substituted by L119 (a3b4), and V111 (a4b2) is replaced by the bulkier I111 (a3b4). This modifies the hydrophobicity,
shape, and space of the binding pocket. Also note the reversal of the positions of the (a4b2) S108 and T157 positions to T108 and S157 (a3b4), which may
affect the hydrogen-bonding network around the cytisine carbonyl.
(D) Cytisine 1 docked into the model of the human a7 (one a subunit in yellow, neighboring a subunit in orange, and cytisine 1 in purple). This model
illustrates that the substitutions include the same serine-threonine switch seen in a3b4; hydrophobic F119 is replaced by a more polar Q119, and V111 of
a4b2 is also replaced with a bulkier leucine.details together with an animation (Video S1) showing a view around the ligand
binding site with cytisine docked into the a4b2 nAChR complex; key residues
are labeled according to the recently reported human a4b2 nAChR crystal
structure PDB: 5KXI and depict the desensitized, non-conducting conformation.41
As expected, the modeled complexes of cytisine 1 and the corresponding C(10)
variants share the core interactions observed in the Ac-AChBP-cytisine complex
(PDB: 4BQT) and as described by Dougherty.27,28 The protonated secondary
amine N(3) binds with a combination of a cation-p interaction and hydrogen
bonding within the a subunit.29 Hydrogen bonds to the side chain of TyrA
(Y100) and the amide carbonyl of TrpB (W156) are also present. (Where applicable,
we adhere to the amino acid nomenclature and numbering scheme used by1720 Chem 4, 1710–1725, July 12, 2018
Dougherty and co-workers.27 For residues [subtype based] outside this scheme,
numbering is according to positions within the crystal structure of the human
a4b2 receptor [PDB: 5KXI].41) The pyridone carbonyl oxygen of cytisine 1 (and
related C(10)-derivatives) is orientated toward the amide nitrogen and carbonyl
of L121 within the protein backbone with space for bridging water molecules (as
present in the crystal structure of varenicline with Ct-AChBP42), providing a
hydrogen-bonding network with the side-chain hydroxyl of S108 (a4b2) or T108
(a3b4 and a7). The crystal structure of nicotine bound in the human a4b2 nAChR
protein is shown in Figure 4A, and models of cytisine 1 bound to the three
receptor subtypes (a4b2, a3b4, and a7) are shown in Figures 4B–4D, illustrating
similar modes of ligand binding in each case. The C(10) position of cytisine 1 is
highlighted by the solid purple sphere showing that a C(10) substituent will project
into the aperture of the active site pocket enabling interactions with residues in
the C loop or the neighboring subunit. For comparison, analogous models of
varenicline 2 in all three receptor subtypes are shown in Figure S4, including a
superposition of varenicline 2 and 10-methylcytisine 10 in the binding site of
human a4b2 subtype.
In addition to performing docking studies, we carried out molecular dynamics (MD)
simulations of the extracellular region of the a4b2, a3b4, and a7 nAChR subtype
complexes with nicotine, cytisine 1, and 10-methylcytisine 10 to better understand
the molecular determinants that modulate ligand binding in these receptors. The
ligands were placed into two of the nAChR binding pockets located at the subunit
interfaces. The resulting complexes were relaxed by energy minimization and equil-
ibrated, andMD simulations were performed for 100 ns without any restraints on the
systems; see the Supplemental Information for full details and graphical outputs. A
simple measure of the overall stability of the protein during the MD simulations can
be obtained by plotting the root-mean-square deviation of the protein atoms with
respect to their initial positions as a function of time. As can be observed in
Figures S5–S8, there was little conformational drift in the overall protein structure
during the simulation time in the nine simulations performed.
In all the nicotine and cytisine 1-bound complexes, the ligand exhibited similar dynamic
behavior such that it remained generally in the same binding orientation (within both
binding pockets 1 and 2) throughout the simulation (Figures S9, S10, and S12). Further-
more, the two canonical interactions between nicotine and TrpB27–29 were always
present (Figures S13 and S14). In contrast, ligand dynamics were more diverse in the
10-methylcytisine 10 complexes (Figures S11 and S12); they showed higher mobility
in the a7 subtype (mainly in binding pocket 2). This increased conformational variability
could be associated with the lower a7 binding affinity (Table 1) and functional potency
(Table S1) observed for 10-methylcytisine 10.
In the a7 subtype, the ligand dynamics were modulated by the behavior of R81.
During the simulation, the flexible side chain of R81 reoriented toward the binding
pocket and moved close to the C(10) methyl of 10 (Video S2). This side-chain move-
ment induced a change in the ligand binding mode, which resulted in the loss of
interactions with TrpB (Figures S13 and S14).
DISCUSSION
This study exploited chemistry to generate a series of potent cytisine derivatives with
enhanced selectivity for a4b2 nAChRs that facilitate an exploration of their molecular
interactions with the nAChR agonist binding sites to provide a rational explanation
of their selectivity profiles.Chem 4, 1710–1725, July 12, 2018 1721
The first observation from the binding data in Table 1 is that 10-methylcytisine 10
binds with higher affinity than 10-hydroxycytisine 6 to each of the receptor subtypes
and in line with the avidity ranking a4b2 > a3b4 > a7. This is consistent with our
modeling, which suggests that binding of the less hydrophilic 10-methyl moiety
(i.e., ligand 10) is favored, as outlined next. The C(10) substituent on the cytisine scaf-
fold is positioned within a hydrophobic region of the binding site in the b subunit.
The hydrophobicity in this region is provided partly by the disulfide linkage in the
a-chain C loop and a conserved leucine residue (b-chain L121) across these three
nAChR subtypes. Furthermore, after comparing the homology models, residue
119 was also identified as potentially playing a key role in subtype discrimination.
In the a4b2 subtype this residue is phenylalanine (F119), whereas the equivalent po-
sitions in the a3b4 and a7 are occupied by leucine and glutamine, respectively. This
decrease in hydrophobicity43,44 in the binding pocket of the a7 subtype could
correlate with the lower binding affinity observed for 10. Other key binding site
residues with the potential to interact with a C(10) substituent are the hydroxyl of
TyrC2 (Y204) and the amide carbonyl oxygen of T157. These residues could,
in the case of 10-hydroxycytisine 6, provide compensatory hydrogen-bonding inter-
actions in an otherwise hydrophobic environment.
Secondly, modeling indicates that the a4b2, a3b4, and a7 nAChR subtypes differ
in terms of the hydrophobic residue located at position 111 situated proximal to
C(9) and C(10) of cytisine 1: residue 111 is valine (in a4b2), isoleucine (in a3b4),
and leucine (in a7). From this, we infer that bulkier residues (I111 and L111) in
this region of the binding site serve to modulate the agonist binding cavity and
are less accommodating of a more sterically demanding C(10)-substituted cytisine
variant.
Our third observation is associated with the differences between receptor subtypes
of the S108-T157 hydrogen-bond network in a4b2. Notably, the position of these
residues is reversed in both a3b4 and a7, i.e., T108 and S157. This inversion might
change not only the shape of the binding pocket but also the hydrogen bonds
formed with the ligand.
Modeling of the three key nAChR subtype complexes allowed us to explore the
wider binding region beyond the primary interactions already established for cyti-
sine 1. This work suggests several interactions specific to cytisine 1 in addition to
those already characterized, some of which would be amenable to further investiga-
tion. These interactions (or some combination of them) might not only help to
explain how cytisine 1 is differentiated from other nicotinic ligands but also suggest
how a C(10) substituent could be exploited to modulate these differences and pro-
vide enhanced selectivity for a4b2 over both a3b4 and a7 nAChRs.
The relationship between cytisine 1, varenicline 2, and the C(10)-variants (e.g., 10)
reported here has been discussed (Figure S4) but raises the options associated
with functionalization of varenicline 2. Within the b subunit, this would involve target-
ing the quinoxaline moiety of 2. This area of varenicline is amenable to C–H activa-
tion45–49 (and other chemistry,50 as are other parts of the scaffold51), and although
quinoxaline-substituted derivatives have been reported, no corresponding biolog-
ical details are available. One of the issues that does arise here and that has signif-
icant implications for any pharmacological assessment is that varenicline 2 is ameso
compound. Monosubstitution within the quinoxaline unit breaks that symmetry, and
although further substitution can resolve that issue, this complicates analysis of any
resulting structure-activity relationship.1722 Chem 4, 1710–1725, July 12, 2018
In conclusion, we have validated C(10) substitution of cytisine 1 as a viable mechanism
for (1) eliciting increased selectivity for a4b2 versus a3b4 and, in particular, a7 nAChR
subtypes; (2) retaining profound partial agonism at a4b2 nAChR; and (3) suppressing
a7 agonism. We have solved the critical challenge of accessing this class of cytisine
ligand by site-specific C‒H functionalization of ()-cytisine by using Ir-catalyzed boryla-
tion. This makes C(10)-substituted cytisine ligands available directly from the parent
compound (i.e., 1) in enantiomerically pure form, and the tractability associated with
this chemistry opens up the range of structural variation that is accessible. We can
now explore the structural determinants required for both binding and function to
further refine nAChR subtype selectivity. In addition, given the relatively low lipophilicity
of cytisine 1 compared with both nicotine and varenicline 2,22 the flexibility enabled by
C–Hactivation chemistry provides an opportunity to identify new cytisine-based ligands
for, e.g., smoking cessation, with improved penetration across the blood-brain barrier
to achieve a more effective therapeutic benefit.
EXPERIMENTAL PROCEDURES
Full details of synthetic chemistry, receptor binding and functional studies, docking,
and MD are provided in the Supplemental Information.
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Supplemental Information includes Supplemental Experimental Procedures, 24 fig-
ures, 2 tables, and 2 videos and can be found with this article online at https://doi.
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